Alba Cereceres
Acute Care · San Antonio, TXNPI 1013661610
Payments from drug & device makers
Across 24 payments — averaging $71.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$311
- Johnson & Johnson$241
- AbbVie$224
- Daiichi Sankyo Inc.$137
- Beigene USA, Inc.$125
- Blueprint Medicines Corporation$125
- plus $544 from 9 others
What the payments were for
- Food & beverage$1,15067%
- Education$55733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $311 |
| Johnson & Johnson | 4 | $241 |
| AbbVie | 2 | $224 |
| Daiichi Sankyo Inc. | 3 | $137 |
| Beigene USA, Inc. | 1 | $125 |
| Blueprint Medicines Corporation | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 1 | $122 |
| Karyopharm Therapeutics Inc. | 2 | $114 |
| Astellas Pharma US Inc | 1 | $100 |
| Incyte Corporation | 1 | $100 |
| Novartis | 1 | $25 |
| Array Biopharma Inc | 1 | $23 |
| Sobi, Inc | 1 | $22 |
| Bristol Myers Squibb | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,707 in reported general payments places this provider in the 80th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $43,877 |
| Ondansetron Hcl | 131 | $1,052 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 59 | $700 |
| Acyclovir | 71 | $627 |
| Letrozole | 20 | $535 |
| Scopolamine | 12 | $420 |
| Dexamethasone | 43 | $402 |
| Gabapentin | 18 | $272 |
| Olanzapine | 31 | $248 |
| Ondansetron OdtOndansetron | 17 | $232 |
| Warfarin Sodium | 22 | $138 |
| Baclofen | 16 | $105 |
| JantovenWarfarin Sodium | 13 | $103 |
| Alendronate Sodium | 14 | $77 |
| Prednisone | 23 | $72 |
Paid to pharmacies, not to this prescriber.
Other acute care in San Antonio
- Christie MorrisonSan Antonio$225K
- Marc KochSan Antonio$20K
- Jessica BjerkSan Antonio$20K
- Tara CummingSan Antonio$12K
- Erin HernandezSan Antonio$10K
- Daniel ChristensenSan Antonio$8K
- Jill FolkertSan Antonio$8K
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.